ATE200781T1 - 4-phenylpiperidin-derivate - Google Patents

4-phenylpiperidin-derivate

Info

Publication number
ATE200781T1
ATE200781T1 AT97926276T AT97926276T ATE200781T1 AT E200781 T1 ATE200781 T1 AT E200781T1 AT 97926276 T AT97926276 T AT 97926276T AT 97926276 T AT97926276 T AT 97926276T AT E200781 T1 ATE200781 T1 AT E200781T1
Authority
AT
Austria
Prior art keywords
alkyl
halo
alkoxy
trifluoroalkyl
alkynyl
Prior art date
Application number
AT97926276T
Other languages
English (en)
Inventor
Franciscus Bernardus Benneker
Dalen Frans Van
Jacobus Maria Lemmens
Theodorus Hendricus Ant Peters
Frantisek Picha
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26647319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE200781(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Application granted granted Critical
Publication of ATE200781T1 publication Critical patent/ATE200781T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97926276T 1997-06-10 1997-06-10 4-phenylpiperidin-derivate ATE200781T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/872,023 US5874447A (en) 1997-06-10 1997-06-10 4-Phenylpiperidine compounds for treating depression
PCT/NL1997/000328 WO1998056787A1 (de) 1997-06-10 1997-06-10 4-Phenylpiperidin-Derivate

Publications (1)

Publication Number Publication Date
ATE200781T1 true ATE200781T1 (de) 2001-05-15

Family

ID=26647319

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926276T ATE200781T1 (de) 1997-06-10 1997-06-10 4-phenylpiperidin-derivate

Country Status (25)

Country Link
US (4) US5874447A (de)
EP (2) EP0994872B9 (de)
JP (1) JP2002503248A (de)
KR (1) KR100543614B1 (de)
AT (1) ATE200781T1 (de)
AU (1) AU3108097A (de)
BG (1) BG64315B1 (de)
BR (1) BR9714787A (de)
CA (1) CA2293247C (de)
CZ (1) CZ295301B6 (de)
DE (2) DE69704679T2 (de)
DK (1) DK0994872T3 (de)
EE (2) EE03970B1 (de)
ES (1) ES2155995T3 (de)
GR (1) GR3035784T3 (de)
HU (1) HUP0003141A3 (de)
IL (1) IL133366A (de)
IS (2) IS1927B (de)
NO (3) NO317371B1 (de)
PL (1) PL188450B1 (de)
PT (1) PT994872E (de)
SI (1) SI0994872T1 (de)
SK (1) SK283394B6 (de)
TR (2) TR200201156T2 (de)
WO (1) WO1998056787A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
AP2000001950A0 (en) * 1998-04-09 2000-12-31 Smithkline Beecham Plc Paroxetine maleate.
US20010023252A1 (en) * 1998-07-02 2001-09-20 Smithkline Beecham Plc Novel compound
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
AU724845B3 (en) * 1998-07-02 2000-09-28 Smithkline Beecham Plc Novel compound
EP1102764A1 (de) * 1998-08-08 2001-05-30 Smithkline Beecham Plc Salze von paroxetin
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9828780D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828779D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828781D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
CA2341984A1 (en) * 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrines or cyclodextrin derivatives
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1280775A1 (de) * 2000-05-12 2003-02-05 Synthon B.V. Tosylsalzen von 4-(p-fluorophenyl)-piperidine-3-carbinolen
ATE257823T1 (de) * 2000-05-12 2004-01-15 Synthon Bv Piperidinverbindungen und verfahren zu deren herstellung
EP1313474A2 (de) * 2000-08-28 2003-05-28 Synthon B.V. Paroxetin-zusammensetzungen und verfahren zu deren herstellung
AU2001286232A1 (en) * 2000-09-14 2002-03-26 Asahi Glass Company, Limited Process for producing paroxetine salt containing substantially no organic solvent
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
WO2002085360A1 (en) * 2001-04-25 2002-10-31 Pentech Pharmaceuticals, Inc. Optimized procedures for the manufacture of paroxetine salts
US6930186B2 (en) * 2001-06-13 2005-08-16 Teva Pharmacetical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
EP1412350A1 (de) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetin isethionatsalz, herstellungsverfahren und anwendung bei der behandlung von depression
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US6717015B2 (en) * 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007058998A2 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
BR112014016197A8 (pt) * 2012-01-31 2017-07-04 Eisai R&D Man Co Ltd derivado de paroxetina
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT99678B (de) * 1921-09-21 1925-04-10 Hoechst Ag Verfahren zur Darstellung arzneilich wirksamer Quecksilberverbindungen.
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (de) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidinderivate mit gastro-intestinaler Wirkung
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
EP0223403B1 (de) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel
US5258388A (en) * 1986-03-17 1993-11-02 University Of Florida Anticholinergic compounds, compositions and methods of treatment
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
JPH08220486A (ja) * 1994-12-14 1996-08-30 Kato Kogei:Kk 眼鏡フレーム
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
BR9608471A (pt) * 1995-05-17 1998-12-29 Novo Nordisk As Processo para a preparação de um composto
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1394160A1 (de) * 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Verfahren zur Herstellung von kristallinem Paroxetin-Hydrochlorid
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
TR199903025T2 (xx) 2000-07-21
TR200201156T2 (tr) 2002-07-22
EE9900570A (et) 2000-08-15
DE29724281U1 (de) 2000-08-10
KR20010013615A (de) 2001-02-26
US5874447A (en) 1999-02-23
EP1078925A1 (de) 2001-02-28
HUP0003141A2 (en) 2001-03-28
CA2293247C (en) 2005-04-12
NO20033766D0 (no) 2003-08-25
WO1998056787A1 (de) 1998-12-17
NO995455D0 (no) 1999-11-08
SK161999A3 (en) 2000-08-14
JP2002503248A (ja) 2002-01-29
NO20033766L (no) 2000-02-09
SK283394B6 (sk) 2003-07-01
EE200200633A (et) 2003-02-17
KR100543614B1 (ko) 2006-01-20
HK1027352A1 (en) 2001-01-12
EE03970B1 (et) 2003-02-17
CZ295301B6 (cs) 2005-07-13
NO317371B1 (no) 2004-10-18
DE69704679D1 (de) 2001-05-31
EP0994872A1 (de) 2000-04-26
NO995455L (no) 2000-02-09
CZ429599A3 (cs) 2000-04-12
US20090326233A1 (en) 2009-12-31
EP0994872B1 (de) 2001-04-25
BG103980A (en) 2000-07-31
AU3108097A (en) 1998-12-30
CA2293247A1 (en) 1998-12-17
SI0994872T1 (de) 2001-08-31
IL133366A (en) 2005-11-20
GR3035784T3 (en) 2001-07-31
IS5249A (is) 1999-11-16
BG64315B1 (bg) 2004-09-30
ES2155995T3 (es) 2001-06-01
DK0994872T3 (da) 2001-05-28
BR9714787A (pt) 2000-07-18
US20010031767A1 (en) 2001-10-18
PL188450B1 (pl) 2005-02-28
IS7098A (is) 2004-01-08
US7598271B1 (en) 2009-10-06
NO20033765L (no) 2000-02-09
US6900327B2 (en) 2005-05-31
HUP0003141A3 (en) 2001-04-28
PT994872E (pt) 2001-09-28
EP0994872B9 (de) 2001-12-05
DE69704679T2 (de) 2001-09-13
NO20033765D0 (no) 2003-08-25
IS1927B (is) 2004-04-15
IL133366A0 (en) 2001-04-30
PL336895A1 (en) 2000-07-17

Similar Documents

Publication Publication Date Title
DE69704679D1 (de) 4-phenylpiperidin-derivate
DK0931788T3 (da) Metalloproteasehæmmere
DE60317198D1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
DK1131315T3 (da) Polyhydroxylerede heterocykliske derivater som antikoagulanter
CY1113054T1 (el) Παραγωγα διαμινης
DK0882019T3 (da) Pyridinderivater som fungicider
AP2001002045A0 (en) FKBP inhibitors.
NZ336091A (en) Aqueous disinfecting cleaning composition
DK0906295T3 (da) Dibenzo-oxazepin- og -dioxepinderivater og deres anvendelse som anti-tumormidler
NO20015202D0 (no) <beta>-hydroksyalkylamider, fremgangsmåte for deres fremstilling og deres anvendelse
NZ333854A (en) Intermediates for the preparation of 2-imidazoline-5-ones
ES2188278T3 (es) Derivados de 3-(heterociclil)-benzoilpirazol.
DK1104419T3 (da) N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse
FI942798A0 (fi) Loracarbef-hydrokloridi-C1-C3-alkoholisolvaatit ja niiden käyttö
DK1140932T3 (da) Derivater af benzo-1,8-naphtyridin

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee